Reach Us +1-217-403-9671
Regulatory Challenges For Nano Therapeutics | 7436
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Regulatory challenges for nano therapeutics

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Lakshmi Durga Vemuri, Sravani Angaru, N.Vishal Gupta and H.V.Raghunandan

Posters: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.007

Nanomedicines are just beginning to enter drug regulatory processes, but within a few decades could comprise a dominant group within the class of innovative pharmaceuticals, the current thinking of government safety and cost-effectiveness regulators appearing to be that these products give rise to few if any nano-specific issues. There are also significant public good aspects to the regulation of nanotechnology, particularly with regard to ensuring that industry involvement in standard-setting does not become a means of reducing competition and that nanotechnology policy and regulation encourages new models of safe drug discovery and development more systematically targeted at the global burden of disease. There is no international regulation of nanoproducts or the underlying nanotechnology. Nor are there any internationally agreed definitions or terminology for nanotechnology, no internationally agreed protocols for toxicity testing of nanoparticles, and no standardized protocols for evaluating the environmental impacts of nanoparticles. In the US, the EPA's nanomaterials stewardship program (NMSP), launched in 2008 and due to be concluded in 2010, was split into two: the basic program, whereby companies were simply required to submit information about the materials they produce; and the in-depth program, which offered companies the opportunity to work with the EPA to identify what additional information might be useful in regulatory decision-making, and to devise methods to generate this information. The European Union has formed a group to study the implications of nanotechnology called the Scientific Committee on Emerging and Newly Identified Health Risks which has published a list of risks associated with nanoparticles.
Lakshmi Durga Vemuri is a student of JSS College of Pharmacy, JSS University, Mysore, Karnataka, India. She has completed her B. Pharm from Chalapathi institute of pharmaceutical sciences,Guntur, Andhrapradesh during the year 2012. Presently she is pursuing M Pharm in Pharmaceutical Quality Assurance in JSS College of Pharmacy, Mysore. She has attended various National and International Conferences. Her current areas of interest are Quality Assurance, Regulatory Affairs, Quality Management Systems, GMP Auditing and analytical method development.